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During the past decade, Helicobacter pylori has become recognized as one of the
most common human pathogens, colonizing the gastric mucosa of almost all persons
exposed to poor hygienic conditions from childhood. It also is often found, albeit with
a lower frequency, in groups of high socioeconomic status. H. pylori causes chronic
active gastritis and is a major factor in the pathogenesis of duodenal ulcers and, to
a lesser extent, gastric ulcers. In addition, the presence of this bacterium is now
recognized as a risk factor for gastric adenocarcinoma and lymphoma. Nevertheless,
most infections appear without clinical consequences. In this second decade of
intensive research, it is important to understand why H. pylori is sometimes a
dangerous pathogen, and to determine how it can be eradicated in those at highest
risk for severe disease.
At the end of the 19th century, several types of
spirochetes and spirilla were observed for the first
time in the stomach of animals (1,2). Beginning at
the turn of the 20th century, similar spiral bacteria
were found in gastrectomy specimens from patients
with gastric cancer and peptic ulcer disease (3,4). In
addition, gastroenterologists and surgeons noted—
but could not explain—the almost universal pres-
ence of antral gastritis in patients with duodenal
ulcers and the frequent presence of atrophic gastri-
tis in patients with gastric ulcer and cancer. Never-
theless, the possibility that peptic ulcer disease or
gastric cancer might be caused by an infectious
agent was generally discounted. The observation
made in 1975 that gram-negative bacteria were
present in 80% of patients with gastric ulcer (5) was
largely ignored by the scientific community which,
at the time, was busily developing potent antiulcer
agents (6). Skepticism remained the overwhelming
reaction to the 1983 reports describing the frequent
association between antral gastritis and the pres-
ence of Campylobacter-like bacteria (7), as well as of
their culture and isolation from patients with gas-
tritis (8). A similar reaction followed the subsequent
demonstration that these Campylobacter-like bacte-
ria were present in almost all patients with gastric
and duodenal ulcers, and were generally associated
with antral gastritis (9). In the past decade, how-
ever, a number of studies have confirmed and ex-
tended these early observations. A consensus
regarding the major role of this bacterium, now
named  Helicobacter pylori, in causing gastroduode-
nal ulceration was formally presented in 1994 (10).
Furthermore, in June 1994, the International
Agency for Research on Cancer Working Group
stated , “H. pylori  plays a causal role in the chain of
events leading to cancer,” referring to adenocarci-
noma and lymphoma of the stomach as well as to the
more benign mucosal-associated lymphoid tissues
(MALT) (11-13).
An important consequence of the considerable
interest generated by these clinical observations is
that extensive bacteriologic and molecular studies
have been performed on this bacterium and similar
organisms. 16S rRNA gene sequence analysis has
revealed important differences between H. pylori
and the closely related Campylobacter, Flexispira,
and Wolinella genuses. These differences have ne-
cessitated the creation of the genus Helicobacter,
which, to date, includes eight gastric, three intesti-
nal, and two hepatic species (14). Each of these
Helicobacter species colonizes different, or a spec-
trum of, mammalian species.
This review summarizes our current knowledge
of the two Helicobacter species that have been ob-
served in the human stomach and reported on ex-
tensively in the literature: H. pylori, the type strain,
and H. heilmannii, also known as Gastrospirillum
hominis (15,16).
Characteristics of Gastric Helicobacters Observed
in Humans
H. pylori, a gram-negative bacterium with a
curved, spiral, or gull-wing shape, is 2.5 to 3.5 mm
long and 0.5 to 1.0 mm in diameter and has a peri-
odicity of 1 to 2 mm. It has smooth surfaces, and one
to six polar-sheathed flagellae emerge from one of
its rounded ends. Since it is morphologically similar
to C. jejuni, it was initially named “pyloric Campy-
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before finally being named H. pylori. This organism
colonizes only the non-acid-secreting mucosa of the
stomach and is not found where parietal cells are
numerous. Thus, it may be observed in the gastric
antrum and the cardia, but also in the corpus, when
atrophic gastritis is present, and attached to the
gastric epithelial cells found in the duodenum, when
gastric metaplasia is present.
G. hominis ( H. heilmannii) is tightly spiraled,
and is 3.5 to 7.5 mm in length and 0.9 mm in diameter;
it has a periodicity of 0.8 to 1 mm and up to 12
flagellae at each pole. 16S rRNA indicates that this
organism belongs to the genus Helicobacter, and is
more closely related to a Helicobacter sp. isolated
from the stomach of cats (H. felis) than to H. pylori
(17). The name H. heilmannii was proposed in honor
of the late German pathologist Heilmann. However,
the subsequent examination of the rRNA of different
clinical isolates indicates that there is enough het-
erogeneity among isolates tentatively identified as
H. heilmannii that it is premature to propose an
official name (17) . This bacterium colonizes only the
parietal cell area of the gastric mucosa and may be
found within parietal cells (18,19).
Diagnosis
H. pylori infection may be diagnosed by harvest-
ing gastric biopsy specimens during endoscopy, by
culturing and isolating the bacterium under mi-
croaerobic conditions (90% N2, 5% O2, and 5% CO2),
and by characterizing the enzymes (urease,
catalase, and oxidase) it produces. Visualization of
the bacterium by light microscopy on slides stained
with hematoxylin and eosin, Gram, Giemsa, Genta,
or Warthin-Starry stain is also of great benefit since
it allows the concurrent diagnosis of the extent of
the antral chronic-active gastritis that H. pylori
causes. However, because H. pylori colonization is
focal, negative biopsy results do not exclude the
possibility of infection in areas not sampled. Infec-
tion also may be diagnosed by determining plasma
and salivary immunoglobulin (Ig) G or IgA levels
with enzyme-linked immunosorbent assays (20,21).
This latter technique is noninvasive, specific, and
sensitive and is believed to reflect the mucosal and
systemic immunity induced by H. pylori infection.
Two other tests, which rely on the production of
urease, also can be used to identify H. pylori. One is
the CLO (for Campylobacter-like organisms) test,
which is performed by placing a mucosal biopsy
specimen in medium containing urea and a pH-
sensitive dye that changes color in the presence of
OH- ions. The second test is the noninvasive 14C or
13C breath test following the oral administration of
14C- or 13C-urea. Neither of these tests is specific for
H. pylori since G. hominis, which generates urease,
also gives a positive reaction. Until specific methods
based on the polymerase chain reaction (PCR) am-
plification of 16S rRNA (17) become widely avail-
able, the diagnosis of G. hominis infection must rely
on histologic morphologic characteristics; histologic
identification must be confirmed by transmission
electron microscopy since other spiral organisms,
e.g., Flexispira rappini, also may be present in the
stomach of humans (22).
Epidemiology
The seroepidemiology of H. pylori has been exten-
sively studied in the United States and in other
countries (23). The high frequency of seropositivity
(up to 100% in some age groups in Albania) and
acquisition of the infection during infancy are char-
acteristic of disadvantaged socioeconomic groups
living in crowded or poor hygienic conditions and
appears to be independent of gender and ethnic
origin. In adults of higher socioeconomic groups, the
rate of seroconversion is estimated at 0.5% per year,
although the frequency of seropositivity increases
with age and may be as high as 40%. A longitudinal
study has indicated that the high frequency of sero-
positivity in older adults might be due to a higher
rate of  H. pylori infection in Western countries in
the years between the two world wars than during
recent years (cohort effect) (24). Alternatively, the
increase in frequency of infection in older adults
might be due to years of low but cumulative risk for
infection. Although the route of transmission for this
infection is not known, the contamination of drink-
ing water may play a role in certain developing
countries (25). In the United States and in other
regions, direct contact and/or consumption of food or
water contaminated by saliva (26), gastric contents,
or feces (27) may be major factors. The recent obser-
vation that H. pylori can be isolated from cats (28)
suggests that transmission from pets to humans (or
humans to pets) is also possible. 
The epidemiology and route of transmission of G.
hominis are largely unknown. The frequency of this
infection appears to range from less than 1% of the
population in industrialized countries (29) to 3% to
8% in developing countries (30). Although the detec-
tion of spirilla in the stomach of cats and dogs
suggests possible transmission from pets, marked
morphologic differences exist between these spirilla
and the organism found in the stomach of humans.
Pathogenicity
H. pylori is considered a pathogen because its
presence is always associated with chronic active
gastritis, and eradication of the bacterium is always
followed by resolution of gastritis. In addition,
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H. pylori gastritis, and ulcer relapse is exceptional
after H. pylori eradication. Thus, the presence of H.
pylori seems necessary for the production of duode-
nal ulcers, with the exception of ulcers attributed to
the use of nonsteroidal antiinflammatory agents or
to the Zollinger-Ellison syndrome (10). The associa-
tion with gastric ulcers is not as strong, although H.
pylori infection is present in 80% of patients with
gastric ulcers who do not consume nonsteroidal anti-
inflammatory agents (10). However, most H. pylori-
infected persons do not report any clinical
symptoms. This may be because these persons are
colonized by less virulent strains or because other
host or bacterial cofactors are required for overt
disease.
In addition, three prospective cohort studies have
demonstrated that H. pylori-infected persons have
an increased risk of developing intestinal-type, but
not undifferentiated, gastric adenocarcinoma (10).
In fact, the association of H. pylori with either gas-
tric ulcer or gastric cancer may be underestimated
in these studies: the atrophic gastritis that follows
long-term infection makes the gastric niche less
hospitable for the bacterium, which may either
eliminate H. pylori or make it difficult to detect.
Nevertheless, atrophic gastritis per se is believed to
be a precancerous lesion that leads to carcinogenesis
without the presence of H. pylori.
The pathogenicity of G. hominis is unclear. The
organism has been associated with upper gastro-
intestinal complaints, and its carriage is generally
accompanied by gastritis, although the inflamma-
tion and gastric atrophy are less than noted with H.
pylori (31,32). In addition, G. hominis was observed
in gastric cancer patients (3) as well as in patients
with only minimal gastritis (29). In this relatively
small number of cases, the frequent concurrent in-
fection with H. Pylori  makes interpreting the re-
spective pathogenic role of either bacterium
difficult. It is probable that G. hominis will turn out
to be at least somewhat pathogenic, as it makes
urease and products of urease action that have been
implicated in inflammation.
Colonization and Virulence Factors
H. pylori multiplies with great efficiency in the
hostile environment within the stomach but sur-
vives poorly in the gastric lumen; it is mainly found
where the pH ranges between 4 and 7, i.e., under the
mucous layer and in close proximity, or even at-
tached, to gastric superficial epithelial cells. The
virulence and the ecologic niche of G. hominis are
unknown, although its presence within parietal
cells of patients with gastrointestinal complaints
(18,19) suggests that it is even more resistant to acid
than H. pylori. 
The production of urease was the first putative
colonization or virulence factor studied. The produc-
tion of this enzyme is shared by the two organisms,
and it may explain their extraordinary ability to
survive in an environment previously considered
sterile because of the presence of proteolytic en-
zymes, as well as the low pH of gastric contents.
Because the ecologic niches of these bacteria are rich
in urea, urease generates OH- ions that neutralize
gastric acid. Although the neutralization of gastric
acid benefits the two bacteria, the production of
hydroxide ions also is toxic to gastric epithelial cells
in vivo, as indicated by in vitro experiments (33).
Two other important virulence factors shared by
H. pylori and G. hominis are their spiral shape and
the motility of their flagellae, which render them
resistant to peristaltic flushing of the gastric con-
tents and enable them to persist in the mucous layer.
Because G. hominis appears to infect fewer persons
than  H. pylori, a more important role might be
attributable to characteristics that are unique to H.
pylori; these include the production of other en-
zymes (catalase, oxidase, protease, and phospholi-
pase), as well as the synthesis of specific adhesin
proteins that enable them to adhere to mucous and
epithelial cells, both in vivo and in vitro (34-36).
The putative virulence factor of H. pylori that has
commanded the most attention during the past few
years has been its vacuolating cytotoxin (vacA gene
product). Intragastric administration of the toxin to
mice causes some (but not all) of the tissue damage
seen in H. pylori-infected persons (37). In addition,
cytotoxin production is highly correlated with the
production of a high molecular weight (120 to 128
kilodaltons) major protein antigen that is called
cytotoxin-associated protein (cagA) and is not the
toxin itself (38).
Diversity of H. pylori
H. pylori isolates may differ with respect to each
of the virulence factors described above; this diver-
sity is likely to contribute to variation in coloniza-
tion or disease. For example, urease-negative
strains have been isolated, and the vacuolating cy-
toxin is produced by only a subset of H. pylori strains
(vacA+ or tox+ strains) (39-41). This observation is
probably clinically relevant because most or all
strains from duodenal ulcer patients, and many
strains from gastric cancer patients, produce cyto-
toxin, whereas only a fraction of strains from pa-
tients with gastritis alone produce the cytotoxin
(42,43). This phenotypic diversity is mirrored in
great diversity on the DNA level. Thus, only cyto-
toxin-producing strains contain the gene for this
cytotoxin-associated protein (cagA) (38,42), al-
though genetic tests have shown that cagA protein
is not needed for toxin production (44). Strains that
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lack the entire cagA gene and additional neighbor-
ing genes. Although the function of the cagA region
is unknown, its presence or absence is easily scored
by hybridization or PCR and thus serves as an easy
marker for probable cytotoxin production and possi-
ble virulence of H. pylori strains. Additional viru-
lence factors are likely to be present. For example,
another recently discovered region constitutes at
least 21 kilobases of the H. pylori genome in hybridi-
zation experiments, and its presence is highly corre-
lated with the presence of cagA: 39 of 40 strains
lacking cagA also lacked this region, and 50 of 52
strains containing cagA contained this region. This
newly discovered region is being called cagII, and
the effort to sequence it is nearly complete (D. E.
Berg, pers. comm.). Preliminary searches have iden-
tified several open reading frames with strong ho-
mologies to virulence functions from other microbes
(45).
 In addition to these extensively studied genes,
genetic diversity of various H. pylori strains can be
demonstrated by the use of two sensitive, efficient,
and reliable PCR-based methods (46,47). This ap-
proach is particularly useful because it allows trac-
ing of strains in epidemiologic studies.
Infection and Immune Response
One of the most puzzling aspects of gastric infec-
tion with H. pylori is its persistence despite intense
local and systemic immune responses. These im-
mune responses are extremely complex and vary
among infected humans. The systemic response is
characterized by a marked increase in plasma IgG,
which remains present for months after the infec-
tion has been cured. The local response includes the
production of IgA, which binds to the surface anti-
gens of H. pylori in vitro and coats the bacterium in
vivo. In addition, infection is consistently associated
with an intense inflammatory response and the in-
filtration of cells into the gastric mucosa. Although
polymorphonuclear cells are often present, most
cells in such infiltrates are mononuclear cells. Both
B and T cells are present, and recent studies have
indicated that the natural killer activity of periph-
eral blood lymphocytes can be increased by H. pylori,
possibly by its stimulating the production of inter-
feron and other cytokines (48). Thus, the long-term
carriage of the infection may be related to the ability
of the bacterium to influence the T-cell response.
Fragmentary evidence also suggests that this infec-
tion can be abortive and cure spontaneously without
the use of antibiotics (A. Dubois and D. E. Berg,
unpublished).
On the other hand, the mucosal response may
promote colonization, as indicated by the observa-
tion that patients with acquired immunodeficiency
syndrome (AIDS) tend to have a lower rate of infec-
tion than aged-matched subjects who are negative
for human immunodeficiency virus (49,50). The lat-
ter study (50) also demonstrated that AIDS patients
had a different pattern of gastritis, characterized by
greater mononuclear cell responses, fewer lymphoid
follicles, and a greater prevalence of intestinal meta-
plasia. The immune response may also prevent the
invasiveness of H. pylori, as suggested by the anec-
dotal but puzzling observation of invasive H. pylori
infection in a patient with AIDS (51).
Treatment
Although H. pylori is sensitive to many antimi-
crobial drugs  in vitro, it is difficult to eradicate from
the stomach. This may be ascribed to antibiotic
breakdown by gastric acid, clearance by gastric emp-
tying, and the difficult-to-penetrate mucous layer in
which the bacterium resides. Resistance of H. pylori
to specific antibiotics, especially metronidazole, is
also frequent. Therefore, it is generally accepted
that a combination of at least two, and possibly
three, antimicrobial agents should be given for a
minimum of 1 week. The regimen found to be most
effective is the administration of amoxicillin (or tet-
racycline) plus metronidazole and bismuth subsali-
cylate 2 to 4 times a day for 2 to 3 weeks (52). The
use of one antibiotic associated with an antisecre-
tory agent, such as a histamine H2 receptor antago-
nist, has given disappointing results. In contrast,
the combination of a proton pump inhibitor (H+-K+
ATPase antagonist) with amoxicillin or acid-stable
macrolides (clarythromycin or roxithromycin) ap-
pears more promising; a number of studies are being
conducted to determine the optimal dose, duration,
concomitant therapy, and cost-effectiveness of these
compounds (53,54). Recently, it was shown that at
least a 7-day course of any of these regimens is
required to obtain a high (90%) cure rate, but that
continuing treatment for more than 10 days does not
significantly improve its efficacy. Finally, topical
therapy for 1 h was recently tried with excellent
results, albeit in only one center at this time (55).
This treatment involves a 2-day administration of a
mucolytic agent to dissolve the mucous layer and of
a proton pump inhibitor. On the third day, a balloon
is introduced into the second portion of the duode-
num under fluoroscopic control, and a solution of
pronase, amoxicillin, metronidazole, and bismuth
subsalicylate is injected into the stomach, where it
is left for 1 h. The presence of the duodenal balloon
appears to prevent emptying of the antibiotics and
the mucolytic agent, thus ensuring maximum effi-
cacy of the therapy.
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The past 12 years have seen extensive progress
in research on H. pylori as a cause of chronic active
gastritis, duodenal ulcer disease, and gastric cancer.
This has been largely due to an unusual collabora-
tion among gastroenterologists, pathologists, mo-
lecular geneticists, bacteriologists, and immuno-
logists. However, our understanding of how H. pylori
colonizes and causes diseases is far from complete,
and it will benefit from studies performed in animal
models that can be experimentally infected with H.
pylori (56-59). In addition, no easily administered
treatment leading to eradication of this bacterium
in all patients is yet available, although a better
knowledge of its physiology may lead to the develop-
ment of such a “silver bullet.” Studies in animals
that are not naturally infected with H. pylori sug-
gest possibilities for vaccines (56,57), and ongoing
trials in nonhuman primates are exploring the pos-
sibility of immunizing hosts that can be naturally
infected with this organism. Although the elimina-
tion of peptic ulcer disease and of certain forms of
gastric cancer will require extensive and coordi-
nated efforts from public health authorities, this
goal now appears to be within the reach of the
scientific and medical community.
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